Clinical and preclinical studies indicated the efficacy and safety of multiple therapies for NSCLC patients with different aberrations, including EGFR exon 19 deletions or exon 21 (L858R) mutations, RET fusion-positive metastatic, ALK genomic tumor aberrations, EGFR exon 20 insertions. This evidence concerns the gene RET and non-small cell lung carcinoma.